Clarity Pharmaceuticals Ltd. has released a press release.
Clarity receives $9.8 million R&D tax incentive refund
Earlier from Clarity Pharmaceuticals
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
- Co-PSMA data published in the European Urology journal
- Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics